We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Requests Additional Study Before Approving Orexigen’s Contrave
FDA Requests Additional Study Before Approving Orexigen’s Contrave
February 4, 2011
Orexigen Therapeutics will have to conduct a new trial evaluating cardiovascular events related to its weight-loss drug Contrave to gain FDA approval, a prospect that could delay an NDA resubmission for several years.